Molecular screening for a personalized treatment approach in advanced adrenocortical cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 10, 2013, Pages 4080-4088

  De Martino, Maria Cristina ^a   Al Ghuzlan, Abir ^a   Aubert, Sebastien ^b   Assié, Guillaume ^c   Scoazec, Jean Yves ^a,d   Leboulleux, Sophie ^a   Do Cao, Christine ^e   Libè, Rossella ^c,f   Nozières, Cécile ^d   Lombès, Marc ^g   Pattou, François ^b   Borson Chazot, Francoise ^d   Hescot, Ségolène ^g   Mazoyer, Clement ^a   Young, Jacques ^h   Borget, Isabelle ^a   Colao, Annamaria ⁱ   Pivonello, Rosario ⁱ   Soria, Jean Charles ^a   Bertherat, Jerome ^c   Schlumberger, Martin ^a   Lacroix, Ludovic ^a   Baudin, Eric ^a   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITÉ LYON 1   (France)

^e Service d'Endocrinologie   (France)

^f INSTITUT NATIONAL DU CANCER   (France)

^g INSERM   (France)

^h BICÊTRE HOSPITAL   (France)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; FIBROBLAST GROWTH FACTOR 9; FIBROBLAST GROWTH FACTOR RECEPTOR 1;

ADRENAL CORTEX TUMOR; ADRENOCORTICAL CANCER; ADULT; ADVANCED CANCER; AGED; ARTICLE; ATM GENE; CANCER STAGING; CDK4 GENE; CDKN2A GENE; CDKN2B GENE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; CTNNB1 GENE; FEMALE; FGF9 GENE; FGFR1 GENE; FRS2 GENE; GENE; GENE SEQUENCE; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION;

EID: 84885227380     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2165     Document Type: Article

References (40)

1. Baudin E, Leboulleux S, Al Ghuzlan A, et al Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011? Horm Cancer. 2011; 2: 363-371.
2. Fassnacht M, Libe R, Kroiss M., Allolio B. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol. 2011; 7: 323-335.
3. Berruti A, Baudin E, Gelderblom H., et al Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23(SUPPL. 7): vii131-138.
4. Fassnacht M, Terzolo M, Allolio B., et al Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012; 366: 2189-2197.
5. Naing A, Lorusso P, Fu S., et al Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013; 108(4): 826-830.
6. Adam P, Hahner S, Hartmann M., et al Epidermal growth factor receptor in adrenocortical tumors: analysisofgene sequence, protein expression and correlation with clinical outcome. Mod Pathol. 2010; 23: 1596-1604.
7. Berruti A, Sperone P, Ferrero A., et al Phase II study of weekly paclitaxel and sorafenibas second/third-line therapyinpatients with adrenocortical carcinoma. Eur J Endocrinol. 2012; 166: 451-458.
8. Gross DJ, Munter G, Bitan M., et al The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R. Endocr Relat Cancer. 2006; 13: 535-540.
9. Kroiss M, Quinkler M, Johanssen S., et al Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab. 2012; 97: 3495-3503.
10. Quinkler M, Hahner S, Wortmann S., et al Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab. 2008; 93: 2057-2062.
11. Wortmann S, Quinkler M, Ritter C., et al Bevacizumab plus cape-citabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol. 2010; 162: 349-356.
12. de Reynies A., Assie G, Rickman D.S., Tissier F., Groussin L, Rene-Corail F. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol. 2009; 27: 1108-1115.
13. Szabo PM, Tamasi V, Molnar V., et al Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed. Oncogene. 2010; 29: 3163-3172.
14. Kotoula V, Sozopoulos E, Litsiou H., Fanourakis G, et al. Mutational analysis of the BRAF, RAS, and EGFR genes in human adrenocortical carcinomas. Endocr Relat Cancer. 2009; 16: 565-572.
15. Ameur N, Lacroix L, Motte N., et al Mutational status of EGFR, BRAF, PI3KCA and JAK2 genes in endocrine tumors. Int J Cancer. 2009; 124: 751-753.
16. Masi G, Lavezzo E, Iacobone M., Favia G, Palu G, Barzon L. Investigation of BRAF and CTNNB1 activating mutations in adrenocortical tumors. J Endocrinol Invest. 2009; 32: 597-600.
17. Tissier F, Aubert S, Leteurtre E., et al Adrenocortical tumors: improving the practice of the Weiss system through virtual microscopy: a National Program of the French Network INCa-COMETE. Am J Surg Pathol. 2012; 36: 1194-1201.
18. Fassnacht M, Johanssen S, Quinkler M., et al Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009; 115: 243-250.
19. Boichard A, Croux L, Al Ghuzlan A, et al Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon. J Clin Endocrinol Metab. 2012; 97(10): E2031-E2035
20. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics (Oxford, England). 2004; 5: 557-572.
21. Karolchik D, Baertsch R, Diekhans M., et al The UCSC Genome Browser Database. Nucleic Acids Res. 2003; 31: 51-54.
22. Dieci MV, Arnedos M, Andre F., Soria JC Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013; 3: 264-279.
23. Laurell C, Velazquez-Fernandez D, Lindsten K., et al Transcriptional profiling enables molecular classification of adrenocortical tumours. Eur J Endocrinol. 2009; 161: 141-152.
24. Brito LP, Ribeiro TC, Almeida M.Q., et al The role of fibroblast growth factor receptor 4 overexpression and gene amplification as prognostic markers in pediatric and adult adrenocortical tumors. Endocr Relat Cancer. 2012; 19: L11-L13.
25. Gupta D, Shidham V, Holden J., Layfield L. Value of topoisomerase IIa, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms. Appl Immunohistochem Mol Morphol. 2001; 9: 215-221.
26. Nakamura M, Miki Y, Akahira J., et al An analysis of potential surrogate markers of target-specific therapy in archival materials of adrenocortical carcinoma. Endocr Pathol. 2009; 20: 17-23.
27. Saeger W, Fassnacht M, Reincke M., Allolio B. Expression of HER-2/neu receptor protein in adrenal tumors. Pathol Res Pract. 2002; 198: 445-448.
28. Tissier F, Cavard C, Groussin L., et al Mutations of β-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005; 65: 7622-7627.
29. Libe R, Groussin L, Tissier F., et al Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res. 2007; 13: 844-850.
30. Wasserman JD, Zambetti GP, Malkin D. Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Mol Cell Endocrinol. 2011; 351: 101-110.
31. Poehlmann A, Roessner A. Importance of DNA damage checkpoints in the pathogenesis of human cancers. Pathol Res Pract. 2010; 206: 591-601.
32. Liberzon E, Avigad S, Stark B., et al. Germ-line ATM gene alterations are associated with susceptibility to sporadic T-cell acute lympho-blastic leukemia in children. Genes Chromosomes Cancer. 2004; 39: 161-166.
33. Rudd MF, Sellick GS, Webb E.L., Catovsky D., Houlston RS. Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lympho-cytic leukemia. Blood. 2006; 108: 638-644.
34. Lahdesmaki A, Kimby E, Duke V., Foroni L, Hammarstrom L. ATM mutations in B-cell chronic lymphocytic leukemia. Haematologica. 2004; 89: 109-110.
35. Ye J, Qi Y, Wang W., et al Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adre-nocortical adenomas. Endocrine. 2012; 41: 479-486.
36. Bourcigaux N, Gaston V, Logie A., Bertagna X, Le Bouc Y, Gicquel C. High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adre-nocortical tumors. J Clin Endocrinol Metab. 2000; 85: 322-330.
37. Dominguez-Brauer C., Brauer PM, Chen Y.J., Pimkina J., Raychaudhuri P. Tumor suppression by ARF: gatekeeper and caretaker. Cell Cycle (Georgetown, Tex.). 2010; 9(1): 86-89.
38. Pilon C, Pistorello M, Moscon A., et al. Inactivation of the p16 tumor suppressor gene in adrenocortical tumors. J Clin Endocrinol Metab. 1999; 84: 2776-2779.
39. Sidhu A, Debelenko L, Misra VK Infantile adrenocortical tumor with an activating GNAS1 mutation. J Clin Endocrinol Metab. 2013; 98: E115-E118.
40. Yalcin S, Kirli E, Ciftci A.O., et al The association of adrenocortical carcinoma and thyroid cancer in a child with Peutz-Jeghers syndrome. J Pediatr Surg. 2011; 46: 570-573.